Treating Patients with RCC and Brain, Liver, or Bone Metastases
Panelists discuss systemic therapy approaches for RCC patients presenting with brain, liver, or bone metastases, noting more limited efficacy of IO-IO therapy in brain metastases and tendencies to use IO-TKI therapy for aggressive or rapidly progressing disease.
EP: 1.Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC
EP: 2.Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC
EP: 3.Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC
EP: 4.Frontline Treatment Approaches for Advanced Clear Cell RCC
EP: 5.Treatment Decisions for Favorable Risk RCC
EP: 6.Managing Immune-Related Toxicities with Frontline RCC Therapies
Now Viewing
EP: 7.Treating Patients with RCC and Brain, Liver, or Bone Metastases
EP: 8.Frontline Therapy for Patients With Non-Clear Cell RCC
EP: 9.Non-Clear Cell RCC: Key Learnings and Future Research Directions
Recent Videos
